MAY 24, 2019 10:14 PM PDT

First Anticoagulant Approved for Pediatric Patients to Treat Potentially Life-Threatening Blood Clots

WRITTEN BY: Nouran Amin

The approval of the drug Fragmin, an anti-coagulant subcutaneous use, will seek to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients—which can include deep vein thrombosis and pulmonary embolism that may lead to death.

VTE can develop as a secondary complication from a broad spectrum of underlying clinical conditions such as a venous catheter, cancer, infection, congenital heart disease, and trauma or surgery and is associated with an increased risk of in-hospital mortality.

Although Fragmin was approved in 1994 for adult patients, it will be the first drug for the pediatric treatment for VTE.

Learn more about VTE:

“Most children who have VTE are fighting a serious underlying primary illness such as cancer or congenital heart disease. Not only are they fighting a serious illness, having a condition like VTE can then lead to significant complications and even death,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

Some issues with Fragmin may include bleeding and hemorrhage amongst other possible complications.

“Prior to this approval, there had been no FDA-approved therapies to treat VTE in pediatric patients. Given the unmet need, we granted the Fragmin application priority review and today we are approving it as the first anticoagulant (blood thinner) indicated for pediatric patients. We remain committed to advancing treatments for children with unmet medical needs.”

Source: Science Daily

 

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 14, 2022
Health & Medicine
CBD and THC are Safe Supplements to Opioid Treatment
APR 14, 2022
CBD and THC are Safe Supplements to Opioid Treatment
A recent study found that it is safe and effective to use cannabidiol (CBD),∆9-tetrahydrocannabinol (THC), and CBD/THC m ...
APR 28, 2022
Health & Medicine
Antidepressants Not Associated Improved Quality of Life
APR 28, 2022
Antidepressants Not Associated Improved Quality of Life
According to a recently published study in PLoS, antidepressants do not improve health-related quality of life (HRQoL) o ...
MAY 13, 2022
Drug Discovery & Development
Promising New Treatment for Cat Litter Parasite T. Gondii
MAY 13, 2022
Promising New Treatment for Cat Litter Parasite T. Gondii
Researchers have discovered a promising therapy for those suffering from toxoplasmosis, a disease caused by a parasite l ...
MAY 20, 2022
Drug Discovery & Development
Drug Shows Promise in treating Spinal Cord Injury
MAY 20, 2022
Drug Shows Promise in treating Spinal Cord Injury
A drug developed by AstraZeneca preserves 80% of nerve function following spinal cord compression injury. The correspond ...
JUN 04, 2022
Drug Discovery & Development
Antibiotics Reduce Motivation to Exercise in Mice
JUN 04, 2022
Antibiotics Reduce Motivation to Exercise in Mice
Antibiotics may decrease athletes' motivation and endurance via effects on the microbiome. The corresponding study w ...
JUN 20, 2022
Health & Medicine
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
JUN 20, 2022
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
The New England Journal of Medicine published results from a small study by researchers at New York’s Memorial Slo ...
Loading Comments...